The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
- PMID: 18395492
- DOI: 10.1016/j.clim.2008.02.006
VSports最新版本 - The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
V体育2025版 - Abstract
Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia. Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib. Dasatinib also inhibits many Src-family tyrosine kinases. We have demonstrated in this study that dasatinib is able to block the function of normal human T-lymphocytes in vitro at clinically relevant concentrations. T-cell functions including proliferation, activation and cytokine production were all uniformly inhibited in the presence of dasatinib. We also demonstrated inhibition of TCR signalling through Src-family kinase LCK, and predicted that inhibition of LCK and other kinases involved in T-cell signalling by dasatinib is responsible for the suppression of T-cell function VSports手机版. These findings raise the concern about potential T-cell inhibition in patients taking dasatinib, and suggest a possible application for the treatment of T-cell mediated immune disorders. .
Publication types
- Actions (V体育官网入口)
VSports注册入口 - MeSH terms
- V体育平台登录 - Actions
- "V体育官网" Actions
- VSports最新版本 - Actions
- Actions (V体育平台登录)
- Actions (VSports app下载)
- VSports - Actions
- "V体育ios版" Actions
- Actions (V体育ios版)
- "V体育2025版" Actions
- "V体育2025版" Actions
- "VSports" Actions
Substances
- "VSports手机版" Actions
- "V体育平台登录" Actions
- "VSports注册入口" Actions
- V体育官网 - Actions
- V体育平台登录 - Actions
- "V体育ios版" Actions
- Actions (V体育安卓版)
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous